In Q3, Aspo reported net sales below consensus (Refinitiv), while adjusted EBIT came in above.
Ferronordic will report its Q3 results on 16 November.
Solid 14% EBIT beat on slightly higher revenues and lower costs Better visibility narrows FY'23 guid...
With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments co...
Lovande data för fostrox Interimsresultaten för fostrox som presenterades i samband med rapporten gj...
Ut i Europa Svedbergs Group, en ledande tillverkare av badrumsprodukter, har genom förvärvet av Rope...
The biggest positive surprise in Aspo’s Q3 result was profitability in Telko segment.
Aspo’s EUR 7.4m Q3 EBIT landed well above estimates.
Loihde’s Q3 saw adj. EBITDA improving 30% y/y, but was below our estimates, at EUR 2.
Redeye comments on the first new data from the phase II trial of EVX-01 in melanoma.
Despite 29% top-line growth in Q3’23, sales were a bit soft due to a slower-than-anticipated ramp-up...
Redeye retains its positive view of Efecte following a Q3 report overall matching our expectations.
I samband med företrädesemissionen har en extern investerare för avsikt att investera minst 1,5 MSEK...
Redeye comments on the outcome of Nanexa’s rights issue, that resulted in a subscription rate of 34.
Redeye comments on the directed share issue of SEK59m to the main institutional investors, which set...
Etteplan’s sales and EBIT for Q3 were lower than expected at EUR 80.
Redeye view the deviation vs our expecations in the Q3 report as more of a timing issue than anythin...
Stark AdTech-tillväxt understryker styrkor i affärsmodellen VO2s intäkter för Q3 uppgick till 74,8 m...
Redeye provides a research update on Lipum following the Q3 report published by the company earlier ...
Redeye har hunnit smälta Eisais presentationer från CTAD och ger en kort reflektion, vi kommer sedan...
